Nano Dimension has announced that its wholly-owned subsidiary, Nano Dimension Technologies has supplied, in return for payment, its flagship DragonFly 2020 3D Printer to Syqe Medical. Syqe is the Tel Aviv-based developer of the world’s first selective-dose, pharmaceutical grade medical cannabis inhaler. It uses 3D printers to prototype and produce inhalers, which have been used in Israel’s Rambam Hospital for more than a year.
Syqe Medical joins the growing ranks of Nano Dimension’s beta clients, and plans to use Nano Dimension’s technology to further develop its inhalers. Nano Dimension’s beta program involves the delivery of the company’s DragonFly 2020 3D Printers to leading companies and partners worldwide through a leasing model.
These customers are pioneering additive manufacturing technology and techniques for electronics and circuitry, and are active in a variety of industries, including: defense, consumer goods, technology for the finance industry and medical devices.
The customers will qualify the DragonFly 2020 technology and will use it to speed up their product development cycles. The DragonFly 2020 3D printer also allows them to strengthen their in-house innovation capabilities, while providing them with enhanced R&D IP security. In return, companies make payments on their leases and provide Nano Dimension with valuable feedback for further product development.